Single-pill alogliptin combination filed in US
This article was originally published in Scrip
Executive Summary
Takeda has filed for the US approval of a single-tablet, fixed-dose combination of its marketed antidiabetic Actos (pioglitazone) and the DPP-4 inhibitor alogliptin, for which a US submission was made at the end of last year.